Horus Pharma, the independent ophthalmic laboratory from Nice, is continuing its European expansion by taking a significant stake in the capital of the Romanian company Inocare Pharm. This strategic acquisition shows the desire of Azuréen, founded in 2003, to consolidate its international presence by relying on players already established and recognized locally.
Based in Bucharest, Inocare Pharm was established ten years ago by Romanian and Italian entrepreneurs and specializes in the marketing of medical devices, dietary supplements for eye health and diagnostic instruments. Employing ten employees, it achieved a 2023 turnover of €3 million, up 25% compared to the previous year.
By joining forces with Horus Pharma, the Romanian company which already collaborates with international manufacturers (OFFHealth in Italy, Optima in Germany or Tear Lab in the United States), Inocare Pharm is expanding its product portfolio by introducing drugs in particular and consolidating its position. on the Romanian market, in the Balkans and the former CIS.
For Horus Pharma, this equity investment provides access to Eastern European markets. “This partnership constitutes an essential growth lever to strengthen our international presence, comments Nicolas Claret, its International Director. By choosing to partner with a firmly established company like Inocare Pharm, we benefit from committed and efficient management as well as an experienced team, capable of meeting the needs of patients and healthcare professionals.”
Horus Pharma, which employs 245 people for a 2023 turnover of €100M, is present in exports in more than 30 countries, but only through subsidiaries or distribution agreements.
